(JSPR) Jasper Therapeutics - Overview
Stock: Antibody, Biologic, Precision, Regenerative
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 94.8% |
| Relative Tail Risk | -7.31% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.12 |
| Alpha | -98.49 |
| Character TTM | |
|---|---|
| Beta | 1.224 |
| Beta Downside | 0.726 |
| Drawdowns 3y | |
|---|---|
| Max DD | 95.77% |
| CAGR/Max DD | -0.61 |
Description: JSPR Jasper Therapeutics December 22, 2025
Jasper Therapeutics (NASDAQ:JSPR) is a clinical-stage biotech founded in 2018 and headquartered in Redwood City, California. Its core platform targets mast-cell and hematopoietic stem-cell pathways, with the lead candidate briquilimab-a monoclonal antibody that blocks stem-cell factor binding to the CD117 receptor. The company is pursuing indications that include chronic spontaneous and inducible urticaria, asthma, and conditioning regimens for stem-cell transplants in sickle-cell disease, Fanconi anemia, and severe combined immunodeficiency.
As of the latest 10-Q, Jasper reported cash and cash equivalents of roughly $120 million, giving it an estimated 18-month runway at its current burn rate of $6–7 million per quarter. The biotech sector remains buoyed by strong venture capital inflows and a historically high valuation premium for early-stage immunology assets, while FDA guidance on mast-cell disorders could materially affect trial timelines. Upcoming Phase 2 data for briquilimab in chronic spontaneous urticaria are slated for Q2 2025, a catalyst that could shift market sentiment.
For a deeper dive into Jasper’s valuation metrics and peer comparison, check out ValueRay’s analyst toolkit.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: -91.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -1.33 > 0.02 and ΔFCF/TA -74.19 > 1.0 |
| NWC/Revenue: 2855 % < 20% (prev 4013 %; Δ -1158 % < -1%) |
| CFO/TA -1.33 > 3% & CFO -76.4m > Net Income -91.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.59 > 1.5 & < 3 |
| Outstanding Shares: last quarter (16.6m) vs 12m ago 10.90% < -2% |
| Gross Margin: 4.26% > 18% (prev 0.41%; Δ 384.9% > 0.5%) |
| Asset Turnover: 1.50% > 50% (prev 2.06%; Δ -0.57% > 0%) |
| Interest Coverage Ratio: -18.37 > 6 (EBITDA TTM -91.9m / Interest Expense TTM 5.06m) |
Altman Z'' -15.00
| A: 0.58 (Total Current Assets 54.6m - Total Current Liabilities 21.0m) / Total Assets 57.5m |
| B: -5.35 (Retained Earnings -307.6m / Total Assets 57.5m) |
| C: -1.18 (EBIT TTM -92.9m / Avg Total Assets 78.4m) |
| D: -6.70 (Book Value of Equity -307.6m / Total Liabilities 45.9m) |
| Altman-Z'' Score: -28.62 = D |
What is the price of JSPR shares?
Over the past week, the price has changed by -8.78%, over one month by -28.95%, over three months by -26.23% and over the past year by -79.33%.
Is JSPR a buy, sell or hold?
- StrongBuy: 7
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the JSPR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.8 | 625.9% |
| Analysts Target Price | 9.8 | 625.9% |
| ValueRay Target Price | 0.8 | -37.8% |
JSPR Fundamental Data Overview February 05, 2026
Revenue TTM = 1.17m USD
EBIT TTM = -92.9m USD
EBITDA TTM = -91.9m USD
Long Term Debt = 1.70m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.70m USD (from shortTermDebt, last quarter)
Debt = 1.70m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -49.2m USD (from netDebt column, last quarter)
Enterprise Value = -8.90m USD (40.3m + Debt 1.70m - CCE 50.9m)
Interest Coverage Ratio = -18.37 (Ebit TTM -92.9m / Interest Expense TTM 5.06m)
EV/FCF = 0.12x (Enterprise Value -8.90m / FCF TTM -76.5m)
FCF Yield = 860.0% (FCF TTM -76.5m / Enterprise Value -8.90m)
FCF Margin = -6519 % (FCF TTM -76.5m / Revenue TTM 1.17m)
Net Margin = -7753 % (Net Income TTM -91.0m / Revenue TTM 1.17m)
Gross Margin = 4.26% ((Revenue TTM 1.17m - Cost of Revenue TTM 1.12m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = -0.15 (set to none) (Enterprise Value -8.90m / Total Assets 57.5m)
Interest Expense / Debt = 297.0% (Interest Expense 5.06m / Debt 1.70m)
Taxrate = 21.0% (US default 21%)
NOPAT = -73.4m (EBIT -92.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.59 (Total Current Assets 54.6m / Total Current Liabilities 21.0m)
Debt / Equity = 0.15 (Debt 1.70m / totalStockholderEquity, last quarter 11.6m)
Debt / EBITDA = 0.54 (negative EBITDA) (Net Debt -49.2m / EBITDA -91.9m)
Debt / FCF = 0.64 (negative FCF - burning cash) (Net Debt -49.2m / FCF TTM -76.5m)
Total Stockholder Equity = 34.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -116.0% (out of range, set to none)
RoE = -261.9% (Net Income TTM -91.0m / Total Stockholder Equity 34.7m)
RoCE = -254.9% (out of range, set to none) (EBIT -92.9m / Capital Employed (Equity 34.7m + L.T.Debt 1.70m))
RoIC = -211.2% (out of range, set to none) (NOPAT -73.4m / Invested Capital 34.7m)
WACC = 10.00% (E(40.3m)/V(42.0m) * Re(10.42%) + (debt cost/tax rate unavailable))
Discount Rate = 10.42% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 22.73%
Fair Price DCF = unknown (Cash Flow -76.5m)
EPS Correlation: -76.08 | EPS CAGR: -10.04% | SUE: 4.0 | # QB: 1
Revenue Correlation: -2.39 | Revenue CAGR: 44.77% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.68 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=-3.09 | Chg30d=+0.203 | Revisions Net=-1 | Growth EPS=+37.0% | Growth Revenue=+0.0%